

## DISCLOSURES

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), the National Foundation for Infectious Diseases (NFID) must ensure balance, independence, objectivity, and scientific rigor in continuing medical education activities. NFID takes responsibility for the content, quality, and scientific integrity of this Continuing Medical Education (CME) activity.

All individuals in a position to control the content of a continuing medical education activity are required to disclose all relevant financial relationships with any ACCME-defined commercial interests for themselves and/or spouse/partner for the past 12 months. Disclosure information is reviewed in advance to manage and resolve any real or perceived conflict of interest that may affect the balance and scientific integrity of an educational presentation.

For details of NFID policies on managing conflicts of interest, visit [www.nfid.org/coi](http://www.nfid.org/coi).

- **Marla Dalton** (NFID Staff) owns stock, stock options, patent, or other intellectual property from Merck & Co., Inc.
- **Daniel R. Feikin** (Speaker) received honoraria from GlaxoSmithKline for serving on the Independent Data Monitoring Committee
- **Bruce G. Gellin** (ACVR Planning Committee) served as an advisor or consultant for Klick Health; and owns stock, stock options, patent(s), or other intellectual property from Teledoc Health
- **Nancy E. Kass** (Speaker) serves as an advisor for Project Baseline, a component of Verily; and has ownership interest in Cycleron Therapeutics, Inc. and Ironwood Pharmaceuticals, Inc.
- **Richard B. Kennedy** (Speaker) has received grant funding and royalties from ICW Healthcare Ventures
- **Nicola P. Klein** (ACVR Planning Committee) received grants or other research support from GlaxoSmithKline, Merck & Co., Inc., Pfizer Inc., Protein Sciences, and Sanofi Pasteur
- **Heidi J. Larson** (Speaker) has received research grants or support from GlaxoSmithKline, Johnson & Johnson, and Merck & Co., Inc.; served as a speaker for GlaxoSmithKline; and is a member of the Merck Vaccine Confidence Advisory Board
- **Ofar Levy** (Speaker) served as an advisor or consultant to GlaxoSmithKline
- **Kathleen M. Neuzil** (ACVR Planning Committee) received grants or other research support from Pfizer Inc.
- **Gregory A. Poland** (ACVR Planning Committee) served as an advisor or consultant for AstraZeneca, Dynavax Technologies Corporation, Eli Lilly and Company, Emergent Biosolutions, Genentech, Genevant Sciences, Inc., GlaxoSmithKline, Johnson & Johnson/Janssen Global Services LLC, Kentucky Bioprocessing Medicago, Merck & Co., Inc., and Sanofi Pasteur; and served as a speaker for Terrapinn
- **Taryn Rogalski-Salter** (ACVR Planning Committee) owns stock, stock options, patent, or other intellectual property from Merck & Co., Inc., Novartis, and Takeda
- **William Schaffner** (NFID Medical Director, ACVR Planning Committee) served as an advisor or consultant for VBI Vaccines

All other speakers, activity planners/reviewers, and staff for this activity have no relevant financial relationships to disclose.